MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the development of AI-powered fatigue recognition technology that analyzes voice patterns and is intended to be added as a commercial feature to the company's Edge AI Intoxication Detection Kiosks. Designed for high-risk industries including aviation, road transport and mining, the fatigue detection module complements MindBio's broader voice-based diagnostics platform aimed at identifying intoxication and neurological impairment, with initial commercial testing of the kiosk platform expected in late second quarter 2026.
This expansion into fatigue detection underscores the potential of voice analysis as a non-invasive, rapid screening tool for cognitive impairment. The technology leverages the same underlying AI model that uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. By extending this capability to fatigue, MindBio aims to address a critical safety concern in industries where operator alertness is paramount.
"The addition of fatigue detection to our platform represents a significant step forward in workplace safety," said a company spokesperson. "Our AI model can identify subtle changes in voice patterns associated with fatigue, providing an objective and immediate assessment without the need for intrusive testing." The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
The implications of this announcement are far-reaching. Fatigue is a known contributor to accidents in transportation, mining, and other high-risk sectors. Traditional fatigue detection methods, such as self-reporting or wearable devices, have limitations in accuracy and compliance. Voice-based diagnostics offer a contactless, passive screening method that could be deployed at entry points or check-in stations, providing real-time data to supervisors.
MindBio's kiosk platform, which includes the fatigue detection module, is expected to undergo initial commercial testing in late Q2 2026. The company's AI prediction model has already demonstrated high accuracy in alcohol intoxication detection, and the addition of fatigue detection could enhance its value proposition for enterprise customers. For more details, visit the full press release at https://nnw.fm/WWgcb.
Investors can find the latest news and updates regarding MBQIF in the company's newsroom at https://nnw.fm/MBQIF. MindBio Therapeutics is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company is focused on developing enterprise solutions for safety-critical industries.
